{"date":"2025-10-14","count":17,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-7784-2025-10-14-1809-1uhskx3","company_id":"7784","company":"安邦生技*","market":"興櫃","industry":"生技醫療","date":"2025-10-14","time":"18:09:02","subject":"公告本公司董事會決議辦理現金增資發行新股","clause":"第9款","fact_date":"2025-10-14","cite_as":"公開資訊觀測站重大訊息：安邦生技*（7784），2025-10-14 18:09，「公告本公司董事會決議辦理現金增資發行新股」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4105-2025-10-14-1802-moftpz","company_id":"4105","company":"東洋","market":"上櫃","industry":"生技醫療","date":"2025-10-14","time":"18:02:48","subject":"公告本公司114年9月份自結合併損益","clause":"第53款","fact_date":"2025-10-14","cite_as":"公開資訊觀測站重大訊息：東洋（4105），2025-10-14 18:02，「公告本公司114年9月份自結合併損益」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7725-2025-10-14-1752-d8h6pu","company_id":"7725","company":"列特博","market":"興櫃","industry":"生技醫療","date":"2025-10-14","time":"17:52:37","subject":"公告本公司一年內累積取得同一有價證券達實收資本額百分之二十","clause":"第17款","fact_date":"2025-10-14","cite_as":"公開資訊觀測站重大訊息：列特博（7725），2025-10-14 17:52，「公告本公司一年內累積取得同一有價證券達實收資本額百分之二十」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4732-2025-10-14-1721-1g43m0g","company_id":"4732","company":"彥臣","market":"興櫃","industry":"生技醫療","date":"2025-10-14","time":"17:21:50","subject":"代子公司公告本公司開發中癌症治療新藥NBM-BMX接獲美國食品藥物管理局(FDA)正式通知，授予轉移性葡萄膜黑色素瘤(Metastatic uveal melanoma,mUM)之「快速審查認定」資格","clause":"第44款","fact_date":"2025-10-14","cite_as":"公開資訊觀測站重大訊息：彥臣（4732），2025-10-14 17:21，「代子公司公告本公司開發中癌症治療新藥NBM-BMX接獲美國食品藥物管理局(FDA)正式通知，授予轉移性葡萄膜黑色素瘤(M」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4732-2025-10-14-1720-16u2prg","company_id":"4732","company":"彥臣","market":"興櫃","industry":"生技醫療","date":"2025-10-14","time":"17:20:31","subject":"代子公司公告「COMPOSITION AND METHOD FOR TREATINGA DRUG-RESISTANT CANCER用於治療抗藥性癌症的組合物和方法」取得加拿大發明專利","clause":"第44款","fact_date":"2025-10-14","cite_as":"公開資訊觀測站重大訊息：彥臣（4732），2025-10-14 17:20，「代子公司公告「COMPOSITION AND METHOD FOR TREATINGA DRUG-RESISTANT C」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6827-2025-10-14-1642-19q8zho","company_id":"6827","company":"巨生醫","market":"興櫃","industry":"生技醫療","date":"2025-10-14","time":"16:42:37","subject":"公告本公司114年度現金增資全體董事放棄認購股數達得認購股數二分之一以上，並洽特定人認購事宜","clause":"第37款","fact_date":"2025-10-14","cite_as":"公開資訊觀測站重大訊息：巨生醫（6827），2025-10-14 16:42，「公告本公司114年度現金增資全體董事放棄認購股數達得認購股數二分之一以上，並洽特定人認購事宜」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6794-2025-10-14-1636-ewok5u","company_id":"6794","company":"向榮生技","market":"上市","industry":"生技醫療","date":"2025-10-14","time":"16:36:10","subject":"公告本公司股票自創新板改列上市買賣日期","clause":"第51款","fact_date":"2025-10-14","cite_as":"公開資訊觀測站重大訊息：向榮生技（6794），2025-10-14 16:36，「公告本公司股票自創新板改列上市買賣日期」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6794-2025-10-14-1635-16h6zzc","company_id":"6794","company":"向榮生技","market":"上市","industry":"生技醫療","date":"2025-10-14","time":"16:35:46","subject":"公告本公司股票改列上市前現金增資收足股款暨現金增資基準日","clause":"第51款","fact_date":"2025-10-14","cite_as":"公開資訊觀測站重大訊息：向榮生技（6794），2025-10-14 16:35，「公告本公司股票改列上市前現金增資收足股款暨現金增資基準日」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7827-2025-10-14-1607-1lowuh","company_id":"7827","company":"漢康-KY創","market":"上市","industry":"生技醫療","date":"2025-10-14","time":"16:07:56","subject":"本公司受邀參加國泰證券舉辦之法人說明會","clause":"第30款","fact_date":"2025-10-15","cite_as":"公開資訊觀測站重大訊息：漢康-KY創（7827），2025-10-14 16:07，「本公司受邀參加國泰證券舉辦之法人說明會」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6827-2025-10-14-1549-1oois3n","company_id":"6827","company":"巨生醫","market":"興櫃","industry":"生技醫療","date":"2025-10-14","time":"15:49:17","subject":"本公司114年第1次現金增資股款催繳公告","clause":"第44款","fact_date":"2025-10-14","cite_as":"公開資訊觀測站重大訊息：巨生醫（6827），2025-10-14 15:49，「本公司114年第1次現金增資股款催繳公告」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6876-2025-10-14-1545-5rax5d","company_id":"6876","company":"朗齊生醫*","market":"興櫃","industry":"生技醫療","date":"2025-10-14","time":"15:45:14","subject":"公告本公司董事會決議員工認股權憑證轉換普通股增資基準日","clause":"第9款","fact_date":"2025-10-14","cite_as":"公開資訊觀測站重大訊息：朗齊生醫*（6876），2025-10-14 15:45，「公告本公司董事會決議員工認股權憑證轉換普通股增資基準日」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-1786-2025-10-14-1530-1pbymtt","company_id":"1786","company":"科妍","market":"上市","industry":"生技醫療","date":"2025-10-14","time":"15:30:37","subject":"公告本公司Eskylage各劑型刺激自體膠原蛋白增生皮下填補劑產品取得銷售許可證書","clause":"第51款","fact_date":"2025-10-14","cite_as":"公開資訊觀測站重大訊息：科妍（1786），2025-10-14 15:30，「公告本公司Eskylage各劑型刺激自體膠原蛋白增生皮下填補劑產品取得銷售許可證書」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4107-2025-10-14-1527-x3pjnm","company_id":"4107","company":"邦特","market":"上櫃","industry":"生技醫療","date":"2025-10-14","time":"15:27:38","subject":"本公司內部稽核主管異動","clause":"第8款","fact_date":"2025-10-14","cite_as":"公開資訊觀測站重大訊息：邦特（4107），2025-10-14 15:27，「本公司內部稽核主管異動」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4102-2025-10-14-1438-109jtcw","company_id":"4102","company":"永日","market":"上櫃","industry":"生技醫療","date":"2025-10-14","time":"14:38:04","subject":"本公司受邀參加元大證券舉辦之線上法說會","clause":"第12款","fact_date":"2025-10-16","cite_as":"公開資訊觀測站重大訊息：永日（4102），2025-10-14 14:38，「本公司受邀參加元大證券舉辦之線上法說會」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-1781-2025-10-14-1435-12robs7","company_id":"1781","company":"合世","market":"上櫃","industry":"生技醫療","date":"2025-10-14","time":"14:35:51","subject":"公告本公司配合檢調單位執行搜索調查","clause":"第19款","fact_date":"2025-10-14","cite_as":"公開資訊觀測站重大訊息：合世（1781），2025-10-14 14:35，「公告本公司配合檢調單位執行搜索調查」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6785-2025-10-14-1428-182uyqk","company_id":"6785","company":"昱展新藥","market":"上櫃","industry":"生技醫療","date":"2025-10-14","time":"14:28:11","subject":"公告本公司收到「LONG-ACTING INJECTABLE FORMULATIONSOF KETAMINE PAMOATE SALTS」日本專利核准通知書。","clause":"第53款","fact_date":"2025-10-14","cite_as":"公開資訊觀測站重大訊息：昱展新藥（6785），2025-10-14 14:28，「公告本公司收到「LONG-ACTING INJECTABLE FORMULATIONSOF KETAMINE PAMOA」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-3176-2025-10-14-1422-8brm4v","company_id":"3176","company":"基亞","market":"上櫃","industry":"生技醫療","date":"2025-10-14","time":"14:22:25","subject":"開發中新藥OBP-301 在歐洲臨床腫瘤學會(ESMO)發表第二期臨床試驗最終成果","clause":"第53款","fact_date":"2025-10-14","cite_as":"公開資訊觀測站重大訊息：基亞（3176），2025-10-14 14:22，「開發中新藥OBP-301 在歐洲臨床腫瘤學會(ESMO)發表第二期臨床試驗最終成果」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}